151 related articles for article (PubMed ID: 18379939)
61. Natural killer/T-cell lymphoma of nasal type with intraocular involvement: case report.
Lee EJ; Kim TW; Heo JW; Yu HG; Chung H
Eur J Ophthalmol; 2010; 20(1):215-7. PubMed ID: 19882515
[TBL] [Abstract][Full Text] [Related]
62. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression.
Gorlick R; Goker E; Trippett T; Steinherz P; Elisseyeff Y; Mazumdar M; Flintoff WF; Bertino JR
Blood; 1997 Feb; 89(3):1013-8. PubMed ID: 9028333
[TBL] [Abstract][Full Text] [Related]
63. Development of chitosan and polylactic acid based methotrexate intravitreal micro-implants to treat primary intraocular lymphoma: an in vitro study.
Manna S; Augsburger JJ; Correa ZM; Landero JA; Banerjee RK
J Biomech Eng; 2014 Feb; 136(2):021018. PubMed ID: 24317155
[TBL] [Abstract][Full Text] [Related]
64. Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells.
Worm J; Kirkin AF; Dzhandzhugazyan KN; Guldberg P
J Biol Chem; 2001 Oct; 276(43):39990-40000. PubMed ID: 11509559
[TBL] [Abstract][Full Text] [Related]
65. Primary intraocular lymphoma: A review.
Choi JY; Kafkala C; Foster CS
Semin Ophthalmol; 2006; 21(3):125-33. PubMed ID: 16912010
[TBL] [Abstract][Full Text] [Related]
66. Clinical outcomes of intravitreal methotrexate injection protocol with a reduced initial frequency for intraocular lymphoma.
Hsu CJ; Hou HA; Lin CP; Lee YJ; Hsu WF; Yeh PT
J Formos Med Assoc; 2022 Jan; 121(1 Pt 2):416-424. PubMed ID: 34112589
[TBL] [Abstract][Full Text] [Related]
67. Toxicity of a biodegradable microneedle implant loaded with methotrexate as a sustained release device in normal rabbit eye: a pilot study.
Palakurthi NK; Correa ZM; Augsburger JJ; Banerjee RK
J Ocul Pharmacol Ther; 2011 Apr; 27(2):151-6. PubMed ID: 21323470
[TBL] [Abstract][Full Text] [Related]
68. Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo.
Mauritz R; Peters GJ; Kathmann I; Teshale H; Noordhuis P; Comijn EM; Pinedo HM; Jansen G
Cancer Chemother Pharmacol; 2008 Nov; 62(6):937-48. PubMed ID: 18283461
[TBL] [Abstract][Full Text] [Related]
69. Comparison of methotrexate polyglutamylation in L1210 leukemia cells when influx is mediated by the reduced folate carrier or the folate receptor. Lack of evidence for influx route-specific effects.
Spinella MJ; Brigle KE; Freemantle SJ; Sierra EE; Goldman ID
Biochem Pharmacol; 1996 Sep; 52(5):703-12. PubMed ID: 8765468
[TBL] [Abstract][Full Text] [Related]
70. Intraocular methotrexate level after high-dose intravenous infusion.
Henson JW; Yang J; Batchelor T
J Clin Oncol; 1999 Apr; 17(4):1329. PubMed ID: 10561199
[No Abstract] [Full Text] [Related]
71. Decreased expression of the human folate receptor mediates transport-defective methotrexate resistance in KB cells.
Saikawa Y; Knight CB; Saikawa T; Page ST; Chabner BA; Elwood PC
J Biol Chem; 1993 Mar; 268(7):5293-301. PubMed ID: 7680349
[TBL] [Abstract][Full Text] [Related]
72. Folate transport and the modulation of antifolate sensitivity in a methotrexate-resistant human breast cancer cell line.
Dixon KH; Trepel JB; Eng SC; Cowan KH
Cancer Commun; 1991; 3(12):357-65. PubMed ID: 16296001
[TBL] [Abstract][Full Text] [Related]
73. Intraocular lymphoma: update on diagnosis and management.
Chan CC; Wallace DJ
Cancer Control; 2004; 11(5):285-95. PubMed ID: 15377987
[TBL] [Abstract][Full Text] [Related]
74. Regulation of folate-binding protein gene expression by DNA methylation in methotrexate-resistant KB cells.
Hsueh CT; Dolnick BJ
Biochem Pharmacol; 1994 Mar; 47(6):1019-27. PubMed ID: 7511899
[TBL] [Abstract][Full Text] [Related]
75. [The immunohistochemical analysis of necropsy eyes and brain lesion in a case of intraocular and brain malignant lymphoma].
Ohshima K; Matsuo N; Shirakawa K; Yoshino T; Akagi T
Nippon Ganka Gakkai Zasshi; 1990 Nov; 94(11):1085-90. PubMed ID: 2075873
[TBL] [Abstract][Full Text] [Related]
76. pH dependence of methotrexate transport by the reduced folate carrier and the folate receptor in L1210 leukemia cells. Further evidence for a third route mediated at low pH.
Sierra EE; Brigle KE; Spinella MJ; Goldman ID
Biochem Pharmacol; 1997 Jan; 53(2):223-31. PubMed ID: 9037255
[TBL] [Abstract][Full Text] [Related]
77. Clinical Characteristics of Primary Vitreoretinal Lymphoma in an Indian Population.
Mahajan S; Nijhawan R; Rajwanshi A; Karkhur S; Mulkutar S; Dogra M; Lal V; Gupta V; Gupta A
Ocul Immunol Inflamm; 2017 Oct; 25(5):633-638. PubMed ID: 27003620
[TBL] [Abstract][Full Text] [Related]
78. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
Soussain C; Suzan F; Hoang-Xuan K; Cassoux N; Levy V; Azar N; Belanger C; Achour E; Ribrag V; Gerber S; Delattre JY; Leblond V
J Clin Oncol; 2001 Feb; 19(3):742-9. PubMed ID: 11157026
[TBL] [Abstract][Full Text] [Related]
79. Restoration of transport activity by co-expression of human reduced folate carrier half-molecules in transport-impaired K562 cells: localization of a substrate binding domain to transmembrane domains 7-12.
Witt TL; Stapels SE; Matherly LH
J Biol Chem; 2004 Nov; 279(45):46755-63. PubMed ID: 15337749
[TBL] [Abstract][Full Text] [Related]
80. Therapeutic vitrectomy for vitreal recurrence of intraocular lymphoma resistant to intravitreal methotrexate post systemic chemotherapy.
Venkatesh P; Gogia V; Khanduja S; Gupta S; Kumar L; Garg S
J Cancer Res Ther; 2015; 11(3):668. PubMed ID: 26458712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
